Author information:
(1)From the Departments of Rheumatology and Clinical Immunology (L.O., P.G., 
R.B., U.S., G.B., F. Hiepe, T.A.), Nephrology and Internal Intensive Care Unit 
(P.E.), Hematology, Oncology and Tumor Immunology (U.R.), and Cardiology and 
Angiology, Campus Mitte (F.K.), Charité-Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin 
Institute of Health (BIH), Deutsches Rheuma-Forschungszentrum (DRFZ) Institute 
of the Leibniz Association (L.O., M.B., P.D., G.A.H., F. Heinrich, A.R., H.E.M., 
M.-F.M., F. Hiepe, T.A.), German Center for Cardiovascular Research (DZHK) 
(F.K.), and BIH Brandenburg Center for Regenerative Therapies (BCRT), 
Charité-Universitätsmedizin Berlin, corporate member of Freie Universität 
Berlin, Humboldt-Universität zu Berlin (M.-F.M.) - all in Berlin; and the 
Laboratory of Inflammation and Autoimmunity, Biomedical Research Foundation, 
Academy of Athens, Athens (P.G.).